Story · Medicine & Biotech
FDA approves Cosentyx for adults with polymyalgia rheumatica
3 outlets · first reported by Patient Worthy on · latest · 10 hours of coverage
The FDA has approved the interleukin-17 inhibitor secukinumab for the treatment of adults with polymyalgia rheumatica, expanding the armamentarium for the disease beyond steroids and a single biologic approved in 2023. Secukinumab (Cosentyx, Novartis) is the second biologic approved by the FDA for… (Healio)
Coverage, in order
-
FDA Approves RYBREVANT FASPRO for Some Adults With Advanced Head and Neck Cancer
The under-the-skin treatment received accelerated approval after a clinical trial found that tumors shrank in some participants whose cancer had returned or spread after earlier treatment. Head and neck squamous cell carcinoma, or HNSCC, begins in the thin, flat cells lining areas such as the…
-
FDA approves Cosentyx for adults with polymyalgia rheumaticaThe FDA has approved the interleukin-17 inhibitor secukinumab for the treatment of adults with polymyalgia rheumatica, expanding the armamentarium for the disease beyond steroids and a single biologic approved in 2023. Secukinumab (Cosentyx, Novartis) is the second biologic approved by the FDA for…
-
FDA approves new drug for advanced head and neck squamous cell carcinomaThe U.S. Food and Drug Administration has approved Janssen Biotech's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after receipt of platinum-based…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.